ライフサイエンスコーパス: clinical improvement

1 treatment with MEDI2070 were associated with clinical improvement.

2 ivocally shown to result in histological and clinical improvement.

3 he active DBS contacts to it correlated with clinical improvement.

4 21 months after IRIS accompanied by delayed clinical improvement.

5 osporine, resulting in rapid and significant clinical improvement.

6 levels in patients and can lead to striking clinical improvement.

7 events and may reduce mortality and time to clinical improvement.

8 us wild-type channels may confer significant clinical improvement.

9 ts with bronchoscopic vapour ablation led to clinical improvement.

10 ons, antifungal therapy is unlikely to yield clinical improvement.

11 presumably limiting NIr exposure and overall clinical improvement.

12 cyclosporine resulted in rapid and sustained clinical improvement.

13 dren hospitalized for bronchiolitis who show clinical improvement.

14 " pulse oximetry readings for those who show clinical improvement.

15 f phototherapy in patients showing excellent clinical improvement.

16 ree had normalization of T-cell function and clinical improvement.

17 eater severity and a 25% reduction indicates clinical improvement.

18 activity was associated with death and poor clinical improvement.

19 showed a linear univariate correlation with clinical improvement.

20 -4% to 1%) and a shorter time to recovery or clinical improvement.

21 can discontinue inotropic therapy because of clinical improvement.

22 ffects at the molecular level paralleled the clinical improvement.

23 ease phenotype and to correlate changes with clinical improvement.

24 x patients resulted in changes suggestive of clinical improvement.

25 patient, whereas 5 of 6 patients with it had clinical improvement.

26 apeutic factor IX expression associated with clinical improvement.

27 subgenual connectivity predicted subsequent clinical improvement.

28 s between disease biomarkers in the skin and clinical improvement.

29 transient elastography, which decreased with clinical improvement.

30 These changes were associated with clinical improvement.

31 the up-grade to CRT-D resulting in enormous clinical improvement.

32 ed on disease-specific targets have shown no clinical improvement.

33 ater in childhood, without any corresponding clinical improvement.

34 ssed associations between MRI parameters and clinical improvement.

35 late the same neural network responsible for clinical improvement.

36 fixed defect size, regional wall motion, and clinical improvement.

37 -1F6, -1F8, and -1F9 mRNAs, concomitant with clinical improvement.

38 relief of anatomic obstruction and sustained clinical improvement.

39 L-1Ra, anakinra, and experienced significant clinical improvement.

40 an inflammatory epitope might translate into clinical improvement.

41 reatment initiation and the delayed onset of clinical improvement.

42 thway is unlikely to be sufficient for clear clinical improvement.

43 prefrontal cortices significantly predicted clinical improvement.

44 l cellular immune response, and there was no clinical improvement.

45 Withdrawal led to rapid clinical improvement.

46 to the right anterior insula correlated with clinical improvement.

47 ued with PLP supplementation associated with clinical improvement.

48 ed in rapid defervescence (median, 4 hr) and clinical improvement.

49 e cost-effective and demonstrate significant clinical improvement.

50 rapy was not significantly associated with a clinical improvement.

51 umulation within the CNS and failed to drive clinical improvement.

52 serine treatment may underlie the associated clinical improvement.

53 able axonal regeneration, remyelination, and clinical improvement.

54 Both treatments resulted in significant clinical improvements.

55 The povidone-iodine group had the highest clinical improvements.

56 and the decrease was accompanied by relevant clinical improvements.

57 determine whether these effects translate to clinical improvements.

58 nge in management 57.7% (45.9% to 69.1%) and clinical improvement 36.6% (26.3% to 47.5%).

59 wo achieved complete remission, 7 partial, 1 clinical improvement, 4 stable disease, and 3 had progre

60 (n = 90), had significantly higher rates of clinical improvement (56.8% vs 28.2%; chi21 = 13.09, P <

61 as common but not universal in non-CLIPPERS [clinical improvement (8/12); radiological improvement (2

62 that connectivity-derived models may inform clinical improvements across DBS targets, surgeons and c

63 All individual macaques showed clinical improvement after hRPE cell implantation compar

64 Case reports provided examples of clinical improvement after PTRAS in patients with acute

65 The group of patients showing no clinical improvement after rituximab therapy were distin

66 Because of the absence of clinical improvement after several antibiotic therapiesa

67 g a JAK-activating CSF3R mutation had marked clinical improvement after the administration of the JAK

68 strengthening with or without NMES enhances clinical improvement after TKA, achieving similar short-

69 Clinical improvement after transplantation correlated wi

70 One patient showed a rapid clinical improvement after treatment with rituximab alon

71 Clinical improvements after CBT-I were correlated with B

72 BOP, PI, and GI showed significant clinical improvements after extractions.

73 most patients with a decline in CSF BDG had clinical improvement, all 3 patients with continually el

74 4 days of treatment initiation, progressive clinical improvement allowed weaning from extracorporeal

75 A progressive clinical improvement along with a reduction of cerebrosp

76 caine nonuse days and associated measures of clinical improvement among cocaine-dependent individuals

77 een the reduction of anti-MAG IgM levels and clinical improvement, an immunological surrogate mouse m

78 18 eyes (81.9%) showed clinical improvement and 4 (18.1%) had decreased SEI whi

79 ed medication for hypertension, demonstrated clinical improvement and amelioration of fibrosis in the

80 time treatment that can provide long-lasting clinical improvement and at the same time prevent the ap

81 The patient did not have any clinical improvement and eventually died after the famil

82 hat lithium plus OPT would result in greater clinical improvement and fewer necessary clinical adjust

83 ation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric

84 topoietic stem cell transplantation reported clinical improvement and inflammatory stabilization in t

85 if these physiologic benefits translate into clinical improvement and outweigh the risk of transfusio

86 sm through which these interventions lead to clinical improvement and potential differences in networ

87 At 1 year, the patient demonstrated good clinical improvement and results of follow-up CSF cultur

88 Capsulotomy and DBS lead to similar clinical improvement and similar metabolic network chang

89 orary) combination therapy results in faster clinical improvement and targeted treatment determines l

90 Two patients presented no clinical improvement and the remaining one experienced a

91 ng interferon-gamma capture, associated with clinical improvement and viral clearance.

92 cause the determinants of ADE are markers of clinical improvement and/or of lower risk of treatment f

93 thin 72 h of admission), resolution (n = 14; clinical improvement) and convalescent (n = 10; first ou

94 unt clinical outcomes, coordination of care, clinical improvement, and electronic information exchang

95 sociated with correction of dysbiosis, rapid clinical improvement, and healing of enterocolitis.

96 vements over placebo, demonstrated trends in clinical improvement, and was well tolerated.

97 uced improvements in MF-SB were annotated as clinical improvement, anemia response, spleen response,

98 Abs are recorded, the mechanisms that convey clinical improvement are incompletely understood.

99 shows promise, but the mechanisms underlying clinical improvement are unknown.

100 ver, the neural substrates that underlie the clinical improvements are not well understood.

101 fter MitraClip procedure are associated with clinical improvement as measured by 6MWT.

102 sgACC and the default mode network predicted clinical improvement, as did more positive amygdala-to-v

103 This change may be related to the clinical improvement, as previously reported, and, toget

104 ity and the antimicrobial treatment regimen, clinical improvement at 1 week (corrected risk ratios [c

105 Clinical improvement at 1 y was relatively better for th

106 at a daily dose of 4 mg was associated with clinical improvement at 12 weeks.

107 magnetic resonance imaging and the extent of clinical improvement at 24 hours as assessed on the Nati

108 his reduction could translate to significant clinical improvement at 6 months post procedure.

109 ssed for clinical outcome, 59 (57%) reported clinical improvement at the last study visit, 23 (22%) w

110 The rates of clinical improvement at week 8 among patients given 9 mg

111 adjuvant Povidone-iodine led to significant clinical improvements at implants.

112 adjuvant povidone-iodine led to significant clinical improvements at implants.

113 hs), (2) improvement of quality of life, (3) clinical improvement (at least 1 Rutherford category), a

114 ics has created a need to estimate potential clinical improvements attributable to increases in cysti

115 and intravenous immunoglobulin, resulting in clinical improvement before chemotherapy.

116 activity after treatment and correlates with clinical improvements better than hematologic response.

117 Foxp3(GFP+) Tregs did not elicit additional clinical improvement but conversely delayed reconstituti

118 for 1 - 13 months; while the eyes which had clinical improvement but had not CSIS score 0 (4 eyes) w

119 PRP) has been shown to result in substantial clinical improvements, but the long-term effects of this

120 At 12 months, clinical improvement by >/=1 Rutherford category without

121 e may reduce mortality, increase recovery or clinical improvement by small to moderate amounts, reduc

122 Clinical improvements can be maintained over long period

123 t of suprabony defects may lead to a greater clinical improvement compared to SPPF alone.

124 usual group (22 subjects) showed significant clinical improvement compared with the treatment-as-usua

125 + EDTA-treated sites showed more significant clinical improvements compared to DOX-beta-TCP-treated s

126 tion of L. rhamnosus SP1 resulted in similar clinical improvements compared with SRP alone.

127 Conversely, clinical improvement correlated inversely with metabolic

128 Clinical improvement correlated with 90-min norketamine

129 A common clinical improvement criterion of -20% or -5 modified Ro

130 flash bother, recorded on daily diaries, and clinical improvement (defined as hot flash frequency >/=

131 of heart failure patients do not demonstrate clinical improvement despite cardiac resynchronization t

132 how long-term persistence of JCV and delayed clinical improvement despite inflammation.

133 Our patient failed to achieve a satisfactory clinical improvement despite treatment with high dose in

134 zole use was not associated with significant clinical improvement despite uniform correction of perip

135 ticipants experienced a comparable degree of clinical improvement, despite receiving fewer treatment

136 rtial response and nine patients (22.5%) had clinical improvement durable for a median of 18 months (

137 nitiates LV reverse remodeling, and provides clinical improvement during 6 months after treatment.

138 Biomarkers predicting the likelihood of clinical improvement during immunotherapy would signific

139 f view, both patients showed biochemical and clinical improvement during the 6 month follow-up and th

140 connected to stimulation sites contribute to clinical improvement effects and whether connectivity is

141 Clinical improvement followed removal of the allograft a

142 d and guanine measured at baseline predicted clinical improvement following four weeks of treatment w

143 nto the molecular mechanisms associated with clinical improvement following NILT.

144 gG1 mAb, results in beneficial, yet limited, clinical improvement for patients with head and neck (HN

145 reduction of emphysematous lobes results in clinical improvement for patients with severe emphysema.

146 ve, well-tolerated treatment providing clear clinical improvements for fludarabine-refractory patient

147 BI 655066 was associated with clinical improvement from week 2 and maintained for up t

148 Most clinical improvements from stimulation occurred early, w

149 not associated with a difference in time to clinical improvement (hazard ratio 1.23 [95% CI 0.87-1.7

150 ditis had higher likelihood of delisting for clinical improvement (hazard ratio, 2.49 [95% confidence

151 tation of riboflavin can lead to significant clinical improvement if started early in the disease pro

152 Successful treatment (clinical improvement; improved follow-up markers and ima

153 ne pathway that signals through STAT3 led to clinical improvement in 1 patient, suggesting a potentia

154 Low-dose IL-2 provides durable clinical improvement in active cGVHD and extended therap

155 The substantial clinical improvement in acute ischemic stroke (AIS) pati

156 ded by International Working Group criteria (clinical improvement in all cases): reduction in spleen

157 Cessation of treatment led to clinical improvement in all cases.

158 The primary outcome was clinical improvement in asthma control over 3 months.

159 Clinical improvement in depressive patients was predicte

160 ion inducement correlates with the degree of clinical improvement in essential tremor.

161 trong correlation between decrease in FA and clinical improvement in hand tremor 3 months after lesio

162 as a close correlation between the degree of clinical improvement in individual patients and reductio

163 Clinical improvement in individuals with PTSD was associ

164 Tildrakizumab demonstrated important clinical improvement in moderate-to-severe psoriasis pat

165 fects of dopamine enhancers, which predicted clinical improvement in motor and motivational deficits.

166 ogation of inflammatory pathways accompanied clinical improvement in multiple studies suggesting that

167 A clinical improvement in nasal allergic symptoms upon cha

168 uded: asymptomatic intracerebral hemorrhage; clinical improvement in NIHSS; and 90-day modified Ranki

169 reatment with triheptanoin resulted in a 90% clinical improvement in non-epileptic paroxysmal manifes

170 MP-8 levels decreased together with observed clinical improvement in patients with gingivitis.

171 ximab over 12 months was not associated with clinical improvement in patients with ME/CFS.

172 ociated with rapid, substantial, and durable clinical improvement in patients with moderate-to-severe

173 and TNF-alpha antagonists may contribute to clinical improvement in patients with psoriasis by impro

174 treatment with rituximab was associated with clinical improvement in patients with refractory ophthal

175 ssue macrophages is a reliable biomarker for clinical improvement in patients with rheumatoid arthrit

176 ies and demonstrates that rapamycin provides clinical improvement in patients with venous malformatio

177 ession of RF may not be sufficient to induce clinical improvement in RA.

178 fatigue response to mild exercise would show clinical improvement in response to treatment strategies

179 quire corticosteroids and showed significant clinical improvement in scores for pain, stiffness, and

180 repair with the MitraClip results in marked clinical improvement in some but not all patients with s

181 itive pressure ventilation have demonstrated clinical improvement in studies of patients refractory t

182 r 16 weeks, we showed a significant pre-post clinical improvement in the DHA group versus placebo, us

183 ll four surviving cohort members experienced clinical improvement in the first decade of life.

184 Cumulative rates of clinical improvement in these patients were 78% in the 5

185 However, the numerical reduction in time to clinical improvement in those treated earlier requires c

186 rm morphology and their loss correlated with clinical improvement in treated patients.

187 To further confirm results, clinical improvements in eight patients from a third cen

188 Brodalumab treatment resulted in significant clinical improvements in patients with moderate-to-sever

189 l operators provided similar average durable clinical improvements in postoperative pain and disabili

190 After CBT, significant clinical improvements in the patient group were observed

191 the tract target based on the first cohort, clinical improvements in the second could be significant

192 Some of the barriers to clinical improvements include the systemic toxicity of c

193 molecular diagnostic test led to significant clinical improvements including reduced time to initiati

194 well tolerated and associated with objective clinical improvement, including sternal wound closure, i

195 The response to ICSs was based on clinical improvements, including a 12% or greater increa

196 Clinical improvement is accompanied by decreases in numb

197 ) reverses established clinical EAE and that clinical improvement is associated with a significant in

198 clinical response to omalizumab and whether clinical improvement is associated with either mast cell

199 While clinical improvement is nearly universal in these patien

200 ncentration is <200 mg/L or 6.2 mmol/L and a clinical improvement is observed.

201 wing surgery, but it is unclear whether this clinical improvement is related to an improvement in OR

202 In some patients, clinical improvements lasted for more than 8 months.

203 tionnaires, clinical photography, subjective clinical improvement, light microscopy, melanin index, r

204 onse (entrainment at month 1 or month 7 plus clinical improvement, measured by the Non-24 Clinical Re

205 necteplase was associated with greater early clinical improvement (median National Institutes of Heal

206 ecteplase-treated patients had greater early clinical improvement (median National Institutes of Heal

207 ockade, but did not result in neuropathic or clinical improvements, most likely due to the late start

208 dentify connections reliably associated with clinical improvement (motor score of the Unified Parkins

209 The clinical improvement observed after training might be me

210 consistent with observed omalizumab-mediated clinical improvement observed in patients with CSU.

211 3-independent mechanism, thus sustaining the clinical improvement observed in patients with IPEX synd

212 This study demonstrated that the clinical improvements observed with the DEX implant were

213 ions, the present findings indicate that the clinical improvements obtained with regenerative surgery

214 Some clinical improvement occurred in both groups of patients

215 Clinical improvement occurred when vemurafenib therapy w

216 rapies that reduce sebum excretion result in clinical improvement of acne.

217 e during dupilumab treatment correlated with clinical improvement of AD and biomarkers of type 2 immu

218 We conclude that clinical improvement of AD that is mediated by interleuk

219 risk" infants and to increasing survival and clinical improvement of affected infants.

220 cell transplantation and demonstrated marked clinical improvement of all IBD-associated clinical symp

221 for the full 18-month period (n = 23) showed clinical improvement of all motor outcomes from baseline

222 sis Research and Treatment (IWG-MRT)-defined clinical improvement of anemia in 8 (19%) and/or decreas

223 and 2 donor-specific antibodies that led to clinical improvement of antibody-mediated rejection and

224 outcome was the percentage of patients with clinical improvement of index symptom at 1 month.

225 The clinical improvement of most patients indicates that ant

226 sia as well as high myopia, with evidence of clinical improvement of motor function over time in the

227 This study is the first to predict clinical improvement of parkinsonian motor symptoms acro

228 Clinical improvement of psoriasis induced by IL-4 treatm

229 ly reduced macrophages in the skin, although clinical improvement of scleroderma was only seen in one

230 insomnia treatment response-that is, marked clinical improvement of symptoms by the Pittsburgh Sleep

231 ultilevel regression analysis indicated that clinical improvement of these parameters was influenced

232 rct glial scar may contribute to the limited clinical improvement often observed after ischemic brain

233 studies will hopefully provide evidence for clinical improvement on the basis of altering treatment

234 CD4+ and CD8+ activity against the JC virus; clinical improvement or stabilization occurred in five o

235 Five patients had clinical improvement or stabilization of PML accompanied

236 ared with those receiving placebo in overall clinical improvements or limitations in work or other ac

237 connectivity were independent predictors of clinical improvement (p < 0.001) and estimated response

238 groups had greater reperfusion (P=0.004) and clinical improvement (P<0.001) at 24 hours than the alte

239 l DHE were all significantly associated with clinical improvement (P<0.01 for all).

240 ites, whereas adjacent sites presented small clinical improvements (P <0.001).

241 Clinical improvement persisted more than 2 weeks followi

242 ed human autoimmune disease, with high-level clinical improvements possible in approximately 90% of p

243 Clinical improvement projects included total hip and kne

244 ith improvement in tics; the model predicted clinical improvement scores (P = 0.003) and was robust t

245 ed with tic improvement; the model predicted clinical improvement scores (P = 0.012) and was robust t

246 ults serve as a possible basis for the small clinical improvement seen in autologous BM cell therapy

247 Because of a lack of clinical improvement several days later, tocilizumab, me

248 we found that only patients with significant clinical improvement showed a significant decrease of pr

249 mab were not associated with any evidence of clinical improvement, so thalidomide and dexamethasone w

250 correlation was found between Treg cells and clinical improvement, suggesting that increases in Treg

251 is, importantly, associated with significant clinical improvement, suggesting that SA promotes the di

252 Marked clinical improvement suggests that eculizumab may be a l

253 remdesivir had a numerically faster time to clinical improvement than those receiving placebo among

254 ted with BRAFis initially exhibit measurable clinical improvement, the majority of patients eventuall

255 atients in both treatment groups experienced clinical improvement, the study did not meet its primary

256 ics for an ARI, patients may attribute their clinical improvement to the antibiotics, regardless of t

257 shows a NK-cell dysregulation, which despite clinical improvement under systemic therapy was only par

258 The primary endpoint was time to clinical improvement up to day 28, defined as the time (

259 Although resulting in a significant clinical improvement, UV-A1 phototherapy was inferior to

260 4+ T-cell count returned to baseline and the clinical improvement waned, possibly due to the patient'

261 Clinical improvement was assessed by monitoring the tape

262 Clinical improvement was assessed on the basis of a modi

263 Clinical improvement was associated with expansion of CD

264 At 40-week treatment, clinical improvement was found significant by both SARA

265 Clinical improvement was greater in patients taking teri

266 Side effects were short-lived, and clinical improvement was maintained for up to 6 weeks wi

267 ed that the effects of DCS administration on clinical improvement was moderated by the level of fear

268 Clinical improvement was observed for 10 of 11 mediator

269 Treatment was well-tolerated and clinical improvement was observed in animal mobility.

270 women; median age, 42 [range, 18-69] years), clinical improvement was observed in parallel with compl

271 alis continua on January 16, 2013, a gradual clinical improvement was observed until March.

272 Clinical improvement was obtained after introduction of

273 Nonetheless, clinical improvement was significant only in younger (ag

274 Neuroimaging indicated that clinical improvement was significantly predicted by stro

275 Clinical improvements were associated with significant g

276 Clinical improvements were consequently noted, though th

277 Increases in enzyme expression and clinical improvements were dose dependent.

278 Correlations with clinical improvements were investigated using the Yale-B

279 Significantly greater clinical improvements were shown in rickets severity, gr

280 n provide incremental information to predict clinical improvement when added to clinical factors and

281 a polymorphism in the D2 gene (DIO2) exhibit clinical improvement when liothyronine (LT3) is added to

282 The clinical improvement with 'stimulation on' compared to '

283 lidation yielded a categorical prediction of clinical improvement with 81% accuracy, 84% sensitivity

284 Our primary outcome was clinical improvement with anti-inflammatory therapy.

285 inflammation the patient demonstrated rapid clinical improvement with conservative treatment.

286 Unexpectedly, transient clinical improvement with fever was noted in 6 patients.

287 rophysiological characterization of observed clinical improvement with fever.

288 Previous research suggested clinical improvement with inhibition of interleukin 23 p

289 Clinical improvement with mild or no symptoms occurred i

290 ts (titer range, 1:10 to >/=1:2,560), due to clinical improvement with targeted therapy and decreasin

291 y of all SMA subtypes, including substantial clinical improvement with the severe and advanced SMA ty

292 Findings were consistent with clinical improvements with CZP plus MTX in both trials.

293 Fourteen patients (93.3%) showed a clinical improvement, with 13 (86.6%) achieving a scleri

294 obustness between the predicted and observed clinical improvement, with an r2 of 0.294 (P < 0.0001).

295 proband with a MEK inhibitor led to dramatic clinical improvement, with remodeling of the patient's l

296 All 4 patients demonstrated striking clinical improvement within 1 month of the initiation of

297 the inflammation and resulted in significant clinical improvement within a few days.

298 ptor antagonist ketamine produced meaningful clinical improvement within hours, suggested that rapid-

299 Both treatments produced significant clinical improvements within the groups.

300 nfliximab administration was associated with clinical improvement without significant adverse events